---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical presentation - signs and symptoms. Topics: Biochemical presentation: rising PSA before imaging or symptoms, Skeletal symptoms: bone pain from bone metastases, Neurological symptoms: spinal cord compression, Urinary symptoms: obstruction from local tumor growth, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Biochemical presentation: rising PSA before imaging or symptoms

> “A rising PSA is typically the first sign of tumor regrowth, followed later by worsening of disease by imaging and the development of clinical symptoms.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.6-2"></a>

### Skeletal symptoms: bone pain from bone metastases

> “Pain in the hips, back (spine), chest (ribs), or other areas , from cancer that has spread to the bones”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

> “Most patients with CRPC have painful bone metastases.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

> “prostate cancer may also present with symptoms of metastases, including bone pain, pathological fractures, or symptoms caused by bone marrow involvement.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

### Neurological symptoms: spinal cord compression

> “Weakness or numbness in the legs or feet , or even loss of bladder or bowel control , from cancer in the spine pressing on the spinal cord”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

<a id="topic-2.2.1.6-4"></a>

### Urinary symptoms: obstruction from local tumor growth

> “Problems urinating , including a slow or weak urinary stream or the need to urinate more often, especially at night”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

> “Nevertheless, local growth of the tumor may produce symptoms of urinary obstruction such as:”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.1.6-5"></a>

### Constitutional symptoms: weight loss and fatigue

> “Weight loss”
> “Feeling very tired”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

<a id="topic-2.2.1.6-6"></a>

### Pattern of metastatic spread at diagnosis of castration resistance

> “Bone metastases were present in ≥80% and visceral metastases in ≤28% of cases at mCRPC diagnosis.”

Source: [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/)

> “Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%).”

Source: [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/)

<a id="topic-2.2.1.6-7"></a>

### Sites of metastasis, all metastatic prostate cancer

> “The most common metastatic sites were bone (84%), distant lymph nodes (10.6%), liver (10.2%), and thorax (9.1%).”

Source: [Gandaglia et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24132735/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
